[BUY] Collins Foods (ASX: CKF) – KFC Australia Holds Steady as Europe Shows Signs of Recovery
Buy, A$10.70 target, 15.4 per cent above the A$9.27 share price, per institutional sell-side research. KFC Australia steady, Europe improving.

Buy, A$10.70 target, 15.4 per cent above the A$9.27 share price, per institutional sell-side research. KFC Australia steady, Europe improving.
Buy: institutional sell-side target A$8.20 for a2 Milk (ASX: A2M) A$7.25 ▼ -1.09%, 11.0 per cent above the share price of A$7.39, as it rebuilds China label sales.
Sell-side Buy, A$30.95 target, 41.8 per cent above the share price of A$21.83. Life360 price rises could lift FY27 and FY28 EBITDA by up to 20 per cent.
Buy rated by institutional sell-side research, target A$45.30, about 29.6 per cent above the share price of A$34.96, after a 1Q27 margin beat.
Buy: institutional sell-side target A$18.20 for Lynas Rare Earths is 38.0 per cent above the share price, with floor prices now on over half its output.

A close New Zealand election puts the coalition deal, and Labour’s 28 per cent capital gains tax on investment property, at the centre for investors.
RBA statements carry only a faint signal on rate moves, and just 29 per cent of Australians know its employment mandate, new research finds.
The RBA has dropped forward guidance and its hedging language has risen since 2023, coinciding with bigger market surprises on decision days.

Buy rated by institutional sell-side research, US$700.00 target, 35.9 per cent upside, as AMD’s Datacenter strength lifts fourth quarter guidance.
Buy, US$215.00 target, 14.8 per cent upside. CoreSite data center growth and a US$2.0 billion buyback offset a soft US leasing quarter for AMT.
Buy rated by institutional sell-side research with a US$915.00 target, 37.5 per cent upside, after Teledyne beat and raised 2026 guidance.
Buy, US$670.00 target, 65.4 per cent upside, per institutional sell-side research. AI equipment demand and higher margin targets drive Applied Materials.
Buy rated by institutional sell-side research with a US$32.00 target, 148.6 per cent upside, ahead of Phase 3 wet AMD gene therapy data in 2Q27.
Defense spending is tilting toward drones, counter-drone systems and munitions on a $1.15 trillion base budget, says institutional sell-side research.
US tech outlook: AI is pushing software spend toward fewer platforms with hard-to-copy data. One example covers more than 240mn US consumers.
Healthcare outlook: new drug launches drive sector growth, with an HIV prevention injection keeping more than 70 per cent of users at six months.
Northern Star Resources received an unsolicited acquisition approach from Gold Fields Limited in September 2026 and promptly rejected it. Chairman Michael Chaney stated the indicative offer fell well short of reflecting the true value of the company. This material...
Lendlease Group Limited (ASX: LLC) A$1.720 ▼ -16.91% responded to an ASX price query on 18 November 2026, clarifying that the sharp 22 percent decline in its share price, from a high of $2.23 on 17 November to $1.74 by market close on 18 November, was not driven by undisclosed material...
Australian United Investment Company Limited has announced a fully franked quarterly dividend of 9 cents per share, payable on 18 December 2026. The distribution relates to the period ending 30 September 2026 and carries full franking at the 30 percent corporate tax...
EML Payments has reported a 100 percent renewal rate on its top 30 client contracts in Q1 FY27, affirming guidance for full-year underlying EBITDA in the A$50-54 million range....
New Hope Corporation has successfully completed the bookbuild for its A$500 million perpetual step-up hybrid securities offering, with the margin set at 4.00% per annum. The...
Finding the best shares to buy on the ASX requires more than just scanning a screener or chasing whatever is up this week. We focus on companies with strong competitive positioning, visible earnings growth, and a catalyst to drive the share price higher over the next...
Dividend investing on the ASX remains one of the most reliable ways to build long-term wealth. Blue chip dividend stocks offer a combination of regular income and capital growth that is difficult to replicate through other strategies, particularly in an environment...
US equities offer Australian investors access to some of the most innovative and fastest-growing companies in the world. The sheer depth of the American market means there are opportunities across sectors that simply do not exist on the ASX, from cutting-edge biotech...
Subscribe today for free and get an alert when we have new research and webinars.
Advise your clients under an established AFSL without building your own. Choose AR or CAR.
Become an AR or CAR
MF & Co. Asset Management is a boutique investment firm offering Equity Capital Markets and derivative general advice & trade execution services.
We are specialists in advising and trading in Australian and US Equities, Index & Equity Options and Options on Futures.
Australia
1300 889 603
International
+61 2 8378 7199
M-F: 8am-5pm
Suite 803, Level 8
70 Pitt St, Sydney, NSW 2000